The proliferative hepatocellular carcinoma (HCC) subtype is associated with aggressive disease and poor prognosis, yet it remains challenging to identify non-invasively. This retrospective multicenter study developed a multitask deep learning system for detecting proliferative…
Continue Reading
Background: Overweight or obesity is a prognostic factor for breast cancer recurrence and breast cancer-related deaths. However, weight control is difficult for breast cancer survivors because of menopause, chemotherapy, anti-hormonal therapy, and psychological issues….
Continue Reading
Dynamic response to therapy is strongly associated with cancer outcomes. We aim to develop the response-adapted individualized risk index (RAIRI) as an individual prognostic approach and predictive biomarker for adjuvant chemotherapy (AC) benefit in…
Continue Reading
The article “Efficacy of a WeChat-Based, Multidisciplinary, Full-Course Nutritional Management Program on the Nutritional Status of Patients With Ovarian Cancer Undergoing Chemotherapy: Randomized Controlled Trial” provided a potential approach to improve the clinical outcomes…
Continue Reading
Tim Barrow-Williams, Head of Drug Delivery at PA Consulting
Bill Hartman, Pharma and Medtech Design Expert at PA Consulting
Last year, the American Cancer Society predicted that in 2024, the US would reach two million annual…
Continue Reading
What You Should Know:
– Oxford Cancer Biomarkers Ltd (OCB), a leader in molecular precision cancer diagnostic tests, has today announced a new partnership with Mira Precision Health Inc.
– This collaboration aims to advance OCB’s…
Continue Reading
Portal Access, an oncology-focused medical device startup, closed a $7 million Series A financing round.The company said that more than 80% of the round was led by U.S. physician investors, including oncologists, interventional radiologists,…
Continue Reading
We developed a practical framework to construct digital twins for predicting and optimizing triple-negative breast cancer (TNBC) response to neoadjuvant chemotherapy (NAC). This study employed 105 TNBC patients from the ARTEMIS trial (NCT02276443, registered…
Continue Reading
BREAKTHROUGH EXPANSION FOR PROSTATE CANCER THERAPY
Novartis has announced a significant development in prostate cancer treatment with the FDA‘s expanded approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan). This radioligand therapy is now available for…
Building accurate prediction models and identifying predictive biomarkers for treatment response in Muscle-Invasive Bladder Cancer (MIBC) are essential for improving patient survival but remain challenging due to tumor heterogeneity, despite numerous related studies. To…
Continue Reading
